CNS Pharmaceuticals, Inc. (CNSP)

CNS Pharmaceuticals, Inc. (CNSP) Healthcare & Pipeline Overview

CNS Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing Berubicin, an anthracycline for treating glioblastoma multiforme. With ongoing Phase I and II clinical trials, CNS Pharmaceuticals aims to address unmet needs in brain and central nervous system tumor therapies, operating within the competitive healthcare landscape.

What Is the Investment Thesis for CNSP?

CNS Pharmaceuticals presents a focused investment opportunity within the biotechnology sector, primarily driven by the clinical development of Berubicin for glioblastoma multiforme. The successful completion of Phase I and II clinical trials and subsequent progression to Phase III could serve as significant value catalysts. The company's partnerships, including those with Houston Pharmaceuticals, The University of Texas M.D. Anderson Cancer Center, and WPD Pharmaceuticals, provide additional support for research and development. However, the company faces inherent risks associated with clinical trials, regulatory approvals, and market competition. With a small market capitalization and limited financial resources, the company's ability to navigate these challenges will be crucial for long-term success. Investors should closely monitor clinical trial outcomes and partnership developments to assess the viability of CNS Pharmaceuticals' pipeline.

Based on FMP financials and quantitative analysis

CNSP Key Highlights

• Berubicin is currently in Phase I and II clinical trials for the treatment of glioblastoma multiforme.
• The company has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center.
• CNS Pharmaceuticals has a development agreement with WPD Pharmaceuticals Inc.
• The company has a collaboration agreement with Reata Pharmaceuticals, Inc.
• CNS Pharmaceuticals was incorporated in 2017 and is based in Houston, Texas.

Who Are CNSP's Competitors?

CNSP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CNSP's Key Strengths?

• Proprietary drug candidate (Berubicin) in clinical development.
• Focus on a specific therapeutic area (brain tumors).
• Established partnerships with research institutions.
• Experienced management team.

What Are CNSP's Weaknesses?

• Limited financial resources.
• Small number of employees.
• Dependence on a single drug candidate.
• Early stage of clinical development.

What Could Drive CNSP Stock Higher?

• Data readout from ongoing Phase I and II clinical trials for Berubicin.
• Potential for new partnerships and collaborations to expand the pipeline.
• Regulatory interactions and potential for accelerated approval pathways.
• Advancements in companion diagnostics to personalize treatment approaches.

What Are the Key Risks for CNSP?

• Financial-distress signal — its Altman Z-Score of -43.09 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory hurdles and delays in obtaining marketing approvals.
• Competition from established pharmaceutical companies with greater resources.
• Dependence on a single drug candidate (Berubicin).
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for CNSP?

• Advancement of Berubicin through Clinical Trials: The successful completion of Phase I and II clinical trials and subsequent progression to Phase III trials for Berubicin represent a significant growth opportunity. Positive clinical data could lead to accelerated regulatory approval and market entry, addressing the unmet need for effective glioblastoma multiforme (GBM) treatments. The GBM market is projected to reach billions of dollars, offering substantial revenue potential for CNS Pharmaceuticals if Berubicin proves to be a viable therapy. Timeline: Ongoing, with Phase III trials contingent on Phase II results.
• Expansion of Pipeline through Strategic Partnerships: CNS Pharmaceuticals can expand its pipeline by forming strategic partnerships and collaborations with other pharmaceutical companies and research institutions. These partnerships can provide access to new drug candidates, technologies, and expertise, accelerating the development of novel therapies for brain and central nervous system tumors. The market for novel cancer therapies is continuously growing, driven by advancements in research and technology. Timeline: Ongoing, with potential for new partnerships in the next 1-3 years.
• Geographic Expansion into International Markets: CNS Pharmaceuticals can pursue geographic expansion into international markets, particularly in Europe and Asia, where there is a growing demand for advanced cancer treatments. Entering these markets would require regulatory approvals and strategic partnerships with local distributors. The global market for cancer therapies is expanding rapidly, driven by aging populations and increasing cancer incidence rates. Timeline: Potential expansion within 3-5 years, contingent on regulatory approvals and market analysis.
• Exploration of Orphan Drug Designation: Pursuing orphan drug designation for Berubicin in the treatment of rare brain tumors could provide CNS Pharmaceuticals with several benefits, including market exclusivity, tax credits, and reduced regulatory fees. This designation can incentivize the development of therapies for underserved patient populations and enhance the commercial attractiveness of Berubicin. The orphan drug market is a growing segment within the pharmaceutical industry, offering significant opportunities for companies focused on rare diseases. Timeline: Application for orphan drug designation within the next year.
• Development of Companion Diagnostics: The development of companion diagnostics to identify patients most likely to respond to Berubicin could improve treatment outcomes and enhance the drug's market positioning. Companion diagnostics can personalize treatment approaches and optimize the use of targeted therapies. The market for companion diagnostics is expanding rapidly, driven by the increasing focus on precision medicine. Timeline: Development of companion diagnostics within 2-4 years, contingent on clinical data and technological advancements.

What Opportunities Does CNSP Have?

• Successful completion of clinical trials.
• Regulatory approval and commercialization of Berubicin.
• Expansion of pipeline through strategic partnerships.
• Orphan drug designation for rare brain tumors.

What Threats Does CNSP Face?

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from established pharmaceutical companies.
• Patent expiration and generic competition.

What Are CNSP's Competitive Advantages?

• Proprietary drug candidate (Berubicin) with patent protection.
• Specialized focus on brain and central nervous system tumors.
• Established partnerships with research institutions and pharmaceutical companies.
• Clinical trial data demonstrating potential efficacy.

What Does CNSP Do?

CNS Pharmaceuticals, Inc. was founded in 2017 and is headquartered in Houston, Texas. The company focuses on developing innovative anti-cancer drug candidates, particularly for the treatment of brain and central nervous system tumors. Their lead drug candidate, Berubicin, is an anthracycline undergoing Phase I and II clinical trials for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer. Berubicin aims to provide a novel therapeutic option for patients with limited treatment alternatives. CNS Pharmaceuticals operates through license agreements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Furthermore, they have a development agreement with WPD Pharmaceuticals Inc. and a collaboration agreement with Reata Pharmaceuticals, Inc., enhancing their research and development capabilities. The company's strategic focus on addressing unmet medical needs in neuro-oncology positions it within a competitive biotechnology landscape, striving to bring innovative therapies to market.

What Products and Services Does CNSP Offer?

• Develop anti-cancer drug candidates.
• Focus on treatments for brain and central nervous system tumors.
• Advance Berubicin, an anthracycline, through clinical trials.
• Conduct Phase I and II clinical trials for glioblastoma multiforme.
• Establish license agreements with research institutions and pharmaceutical companies.
• Collaborate with other companies to enhance research and development.

How Does CNSP Make Money?

• Develop and license pharmaceutical products.
• Conduct clinical trials to demonstrate drug efficacy and safety.
• Partner with other companies for research and development.
• Seek regulatory approvals for commercialization.

What Industry Does CNSP Operate In?

CNS Pharmaceuticals operates within the biotechnology industry, specifically focusing on oncology and drug development for brain tumors. The market for glioblastoma multiforme (GBM) treatments is driven by the high unmet medical need and limited therapeutic options. The biotechnology industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. CNS Pharmaceuticals' success depends on its ability to navigate these challenges and bring Berubicin to market effectively. The company's partnerships and collaborations are crucial for leveraging resources and expertise in this competitive landscape.

Who Are CNSP's Key Customers?

• Patients with brain and central nervous system tumors.
• Healthcare providers specializing in oncology.
• Hospitals and cancer treatment centers.
• Pharmaceutical companies through licensing and collaboration agreements.

CNSP Valuation & Market Position

With a $2.86M market cap, CNS Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CNSP's quantitative score of 25/100 is below the peer average of 79/100.

Net buyingInsider Activity

Over the past six months, CNS Pharmaceuticals, Inc. insiders filed 3 SEC Form 4 transactions — 0 sales and 3 purchases. On net that is roughly 26K shares acquired (about $34K) — insiders putting money in tends to read as conviction.

FY2026 estForward Outlook

Wall Street analysts project CNS Pharmaceuticals, Inc. revenue of about $40.8M for fiscal 2026, with EPS near $-1.65.

F-Score 1/9Financial Health

CNS Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -43.09 places it in the distress zone, a signal of elevated financial risk.

CNSP Financials

CNSP Latest News

CNSP Analyst Consensus

CNSP MoonshotScore

Common Questions About CNSP (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources